Clinical nuclear medicine, cilt.48, sa.5, 2023 (SCI-Expanded)
Papillary renal cell cancer is a rare malignancy with limited treatment options in the advanced stage of the disease. We present the case of a 62-year-old man with progressive left-sided papillary renal cell carcinoma who underwent 68Ga-FAPI (fibroblast activated protein inhibitor)-04 and 18F-FDG PET/CT imaging. 68Ga-FAPI-04 PET/CT demonstrated variable FAP expression in all metastatic lesions detected by 18F-FDG PET/CT, including multiple lymph nodes, bone, and thyroid. This case highlights that FAP-Targeted imaging can be a promising modality for diagnostic and theranostic use in papillary renal cell carcinoma.